The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
OXYCODONE-HAMELN (Hameln Pharma Pty Ltd)
Product name
OXYCODONE-HAMELN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
121 (255 working days)
Active ingredients
oxycodone hydrochloride
Registration type
New generic medicine
Indication
OXYCODONE-HAMELN (solution for injection) is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.